Zimmer Biomet Holdings Inc ZBH

Morningstar Rating
$94.08 +2.74 (3.00%)
View Full Chart

Company Report

Zimmer Biomet Faces Management and Operational Changes, but Wide Moat Remains Constant

Zimmer Biomet is the market leader in large-joint reconstruction, and we expect aging baby boomers and improving technology suitable for younger patients to fuel solid demand for hip and knee replacement that should offset price declines. Zimmer stumbled into a series of pitfalls in 2016-17, including integration issues, supply and inventory challenges, and quality concerns. The firm's efforts to turn itself around have been admirable, though the pandemic slowed progress. Despite all the improvement, the firm still hasn't reached consistent growth and profitability gains.

Price vs Fair Value

ZBH is trading at a LOCK|>G$LBn premium.
Price
$94.08
Fair Value
!bl
Uncertainty
LOCK|&#%>y
1-Star Price
LOCK|#.&
5-Star Price
H?p
Economic Moat
LOCK|HZ
Capital Allocation
LOCK|M?np>$Z

Bulls Say, Bears Say

Bulls

Zimmer Biomet has made impressive progress in placing its Rosa robots in hospitals and ambulatory surgical centers, paving the way for higher-margin implant pull-through.

Bears

The scarcity of high-quality comparative effectiveness research data makes it more difficult for orthopedic companies to secure premium pricing at the same time payers and hospitals are raising the bar for cost-effectiveness.

News

Articles & Videos

Trading Information

Previous Close Price
$91.34
Day Range
$91.2595.48
52-Week Range
$79.12108.29
Bid/Ask
$92.60 / $93.99
Shares Outstanding
193.46M
Market Cap
$18.20B
Volume/Avg
3M / 2M

Key Statistics

Price/Earnings (Normalized)
11.09
Price/Sales
2.21
Dividend Yield (Trailing)
1.02%
Dividend Yield (Forward)
1.02%
Total Yield
3.81%

Company Profile

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Value
Total Number of Employees
17,000

Competitors

Valuation

Metric
ZBH
JNJ
SNN
Price/Earnings (Normalized)
11.0924.0214.52
Price/Book Value
1.447.642.50
Price/Sales
2.216.512.20
Price/Cash Flow
9.9121.0711.71
Price/Earnings
ZBH
JNJ
SNN

Financial Strength

Metric
ZBH
JNJ
SNN
Quick Ratio
0.750.771.40
Current Ratio
1.731.033.00
Interest Coverage
4.0624.094.46
Quick Ratio
ZBH
JNJ
SNN

Profitability

Metric
ZBH
JNJ
SNN
Return on Assets (Normalized)
7.33%13.33%
Return on Equity (Normalized)
13.30%32.77%
Return on Invested Capital (Normalized)
9.54%20.14%
Return on Assets
ZBH
JNJ
SNN

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|^hCgT&RLOCK|$sTb$160B
Stryker Corp
SYK
LOCK|c#<&tXFRLOCK|$mJ$127B
Medtronic PLC
MDT
LOCK|%r?!G$NLOCK|<RL!$107B
Boston Scientific Corp
BSX
LOCK|<$g$!mDLOCK|Nx@<$66B
Edwards Lifesciences Corp
EW
LOCK|?&Bv@hNLOCK|>$bDr$53B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|%#tbdWCLOCK|<>T$30B
DexCom Inc
DXCM
LOCK|>M^WbH^zLOCK|yJ^^$29B
Koninklijke Philips NV ADR
PHG
LOCK|C#LOCK|?^$27B
Steris PLC
STE
LOCK|NZLF%%LOCK|BqT^$21B

Sponsor Center